Hepion Launches Next-Gen Liquid Biopsy Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Strategic Shift: Hepion Pharmaceuticals has signed a licensing agreement with Cirna Diagnostics to acquire a novel circulating tumor RNA (ctRNA) biomarker assay for early diagnosis of hepatocellular carcinoma, reflecting the company's strategic pivot towards clinically validated liquid biopsy tests under new leadership.
- Market Demand: Hepatocellular carcinoma accounts for 75-90% of liver cancer cases and is the sixth most common cancer globally, highlighting an urgent need for early detection solutions, as current surveillance methods miss up to 75% of early-stage cancers.
- Technological Advantage: The ctRNA platform detects RNA signals shed by tumors, offering earlier cancer detection capabilities compared to DNA-based tests, and has been validated across multiple independent cohorts, enhancing specificity for hepatocellular carcinoma with broad clinical application potential.
- Commercial Outlook: The global liquid biopsy market is currently valued at $10 billion, projected to reach nearly $9 billion in the U.S. alone by 2035, positioning Hepion's ctRNA and mSEPT9 diagnostic technologies to capitalize on significant commercial opportunities and strengthen its leadership in early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
